RT Journal Article
SR Electronic
T1 Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.12.24313545
DO 10.1101/2024.09.12.24313545
A1 Xu, Hanmeng
A1 Aparicio, Camilla
A1 Wats, Aanchal
A1 Araujo, Barbara L.
A1 Pitzer, Virginia E.
A1 Warren, Joshua L.
A1 Shapiro, Eugene D.
A1 Niccolai, Linda M.
A1 Weinberger, Daniel M.
A1 Oliveira, Carlos R.
YR 2024
UL http://medrxiv.org/content/early/2024/09/12/2024.09.12.24313545.abstract
AB IMPORTANCE Nirsevimab, a long-acting monoclonal antibody, has demonstrated efficacy against RSV-related lower respiratory tract infections (LRTIs) in clinical trials. Post-licensure monitoring is essential to confirm these benefits in real-world settings.OBJECTIVE To evaluate the real-world effectiveness of nirsevimab against medically attended RSV infections in infants and to assess how effectiveness varies by disease severity, dosage, and time since immunization.DESIGN, SETTING, AND PARTICIPANTS This test-negative case-control study used inpatient, outpatient, and emergency room data from the Yale New Haven Health System. Nirsevimab-eligible infants who were tested for RSV using polymerase chain reaction between October 1, 2023 and May 9, 2024 were included. Cases were infants with confirmed RSV infections; controls were those who tested negative.EXPOSURE Nirsevimab immunization, verified through state immunization registries.MAIN OUTCOMES AND MEASURES Effectiveness was estimated using multivariable logistic regression, adjusting for age, calendar month, and individual risk factors. Separate models examined effectiveness by clinical setting, disease severity, dose, and time since immunization. Broader outcomes, including all-cause LRTI and LRTI-related hospitalization, were also analyzed, with stratification by early and late respiratory seasons.RESULTS The analytic sample included 3,090 infants (median age 6.7 months, IQR 3.6-9.7), with 680 (22.0%) RSV-positive and 2,410 (78.0%) RSV-negative. 21 (3.1%) RSV-positive and 309 (12.8%) RSV-negative infants received nirsevimab. Effectiveness against RSV infection was 68.4% (95% CI, 50.3%-80.8%). Effectiveness was 61.6% (95% CI, 35.6%-78.6%) for outpatient visits and 80.5% (95% CI, 52.0%-93.5%) for hospitalizations. The highest effectiveness, 84.6% (95% CI, 58.7%-95.6%), was observed against severe RSV outcomes requiring ICU admission or high-flow oxygen. Although effectiveness against RSV infections declined over time, it remained significant at 55% (95% credible interval, 16%-75%) at 14 weeks post-immunization. Protective effectiveness was also observed against all-cause LRTI and LRTI-related hospitalizations during peak RSV season (49.4% [95% CI, 10.7%-72.9%] and 79.1% [95% CI, 27.6%-94.9%], respectively). However, from February to May, when RSV positivity was low, effectiveness against these broader outcomes was negligible.CONCLUSIONS AND RELEVANCE Nirsevimab provided substantial protection against RSV-related outcomes for at least three months. These findings support the continued use of nirsevimab and provide evidence that may help build public confidence in the immunization program.Question What is the effectiveness of nirsevimab against medically attended respiratory syncytial virus (RSV) infections in infants?Findings 680 RSV test-positive cases and 2,410 RSV test-negative controls were included in this test-negative case-control study. Nirsevimab’s effectiveness was 69% against RSV infections, 81% against RSV-associated hospitalization, and 85% against severe RSV disease. Effectiveness against RSV infection declined from 79% at 2 weeks post-immunization to 55% at 14 weeks post-immunization.Meaning Nirsevimab provides strong protection against a wide range of RSV outcomes, but its effectiveness diminishes over time. These data can be utilized to optimize nirsevimab’s implementation and sustain its uptake.Competing Interest StatementVEP was previously a member of the WHO Immunization and Vaccine- related Implementation Research Advisory Committee (IVIR-AC). All other authors declare no conflicts of interest.Funding StatementThis work was supported in part by the National Institutes of Health (NIH) grant numbers R01AI179874 (CRO) and K23AI159518 (CRO). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board (IRB) at the Yale University School of Medicine approved the study (HIC:2000036550).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesExternal researchers can make written requests to the corresponding author for sharing of completely de-identified and aggregate-level data. Data are available for researchers to allow replication of results provided all ethical and legal requirements are met. Requests will be assessed on a case-by-case basis in consultation with the lead and co-investigators. All data sharing will abide by rules and policies defined by the involved parties. Data-sharing mechanisms will ensure that the rights and privacy of individuals participating in research will be protected at all times. The study protocol and statistical code used are also available on request from the corresponding author.